Search

Your search keyword '"Jacqz-Aigrain, Evelyne"' showing total 22 results
Start Over Author "Jacqz-Aigrain, Evelyne" Publication Year Range Last 3 years
22 results on '"Jacqz-Aigrain, Evelyne"'

2. Use of Machine Learning for Dosage Individualization of Vancomycin in Neonates

Author

Tang, Bo-Hao, Zhang, Jin-Yuan, Allegaert, Karel, Hao, Guo-Xiang, Yao, Bu-Fan, Leroux, Stephanie, Thomson, Alison H., Yu, Ze, Gao, Fei, Zheng, Yi, Zhou, Yue, Capparelli, Edmund V., Biran, Valerie, Simon, Nicolas, Meibohm, Bernd, Lo, Yoke-Lin, Marques, Remedios, Peris, Jose-Esteban, Lutsar, Irja, Saito, Jumpei, Jacqz-Aigrain, Evelyne, van den Anker, John, Wu, Yue-E., and Zhao, Wei

Published
2023
Full Text
View/download PDF

6. Modalités pratiques de prise en charge en cours de traitement d’entretien des leucémies aiguës lymphoblastiques pédiatriques : recommandations du Comité leucémies de la Société française de lutte contre les cancers et les leucémies de l’enfant et de l’adolescent (SFCE)

Author

Saultier, Paul, Simonin, Mathieu, Beaumais, Tiphaine Adam de, Rialland, Fanny, Alby-Laurent, Fanny, Lubnau, Marion, Desplantes, Claire, Jacqz-Aigrain, Evelyne, Rohrlich, Pierre, Reguerre, Yves, Rabian, Florence, Sirvent, Nicolas, Plat, Geneviève Willson, and Petit, Arnaud

Published
2022
Full Text
View/download PDF

7. Agreement between a regional pharmacovigilance centre and an adjudication committee regarding adverse drug reactions on a cohort of hospitalised children

Author

Pages, Nicolas, Bounabi, Anissa, Boussaha, Inesse, Ndiaye, Marietou, Portefaix, Aurélie, Simeon, Gaelle, Guy, Claire, Stagnara, Jean, Paret, Nathalie, Vial, Thierry, Eftekhari, Pirayeh, Floret, Daniel, Gajdos, Vincent, Langhendries, Jean-Paul, Bleyzac, Nathalie, Alberti, Corinne, Jacqz-Aigrain, Evelyne, Nguyen, Kim An, and Kassai, Behrouz

Published
2022
Full Text
View/download PDF

9. Drug Clearance in Neonates: A Combination of Population Pharmacokinetic Modelling and Machine Learning Approaches to Improve Individual Prediction

Author

Tang, Bo-Hao, Guan, Zheng, Allegaert, Karel, Wu, Yue-E., Manolis, Efthymios, Leroux, Stephanie, Yao, Bu-Fan, Shi, Hai-Yan, Li, Xiao, Huang, Xin, Wang, Wen-Qi, Shen, A.-Dong, Wang, Xiao-Ling, Wang, Tian-You, Kou, Chen, Xu, Hai-Yan, Zhou, Yue, Zheng, Yi, Hao, Guo-Xiang, Xu, Bao-Ping, Thomson, Alison H., Capparelli, Edmund V., Biran, Valerie, Simon, Nicolas, Meibohm, Bernd, Lo, Yoke-Lin, Marques, Remedios, Peris, Jose-Esteban, Lutsar, Irja, Saito, Jumpei, Burggraaf, Jacobus, Jacqz-Aigrain, Evelyne, van den Anker, John, and Zhao, Wei

Published
2021
Full Text
View/download PDF

10. A physiological approach to renal clearance:From premature neonates to adults

Author

Holford, Nick, O'Hanlon, Conor J., Allegaert, Karel, Anderson, Brian, Falcao, Amilcar, Simon, Nicolas, Lo, Yoke-Lin, Thomson, Alison H., Sherwin, Catherine M., Jacqz-Aigrain, Evelyne, Llanos-Paez, Carolina, Hennig, Stefanie, Mockus, Linas, Kirkpatrick, Carl, Holford, Nick, O'Hanlon, Conor J., Allegaert, Karel, Anderson, Brian, Falcao, Amilcar, Simon, Nicolas, Lo, Yoke-Lin, Thomson, Alison H., Sherwin, Catherine M., Jacqz-Aigrain, Evelyne, Llanos-Paez, Carolina, Hennig, Stefanie, Mockus, Linas, and Kirkpatrick, Carl

Abstract

Aims: We propose using glomerular filtration rate (GFR) as the physiological basis for distinguishing components of renal clearance. Methods: Gentamicin, amikacin and vancomycin are thought to be predominantly excreted by the kidneys. A mixed-effects joint model of the pharmacokinetics of these drugs was developed, with a wide dispersion of weight, age and serum creatinine. A dataset created from 18 sources resulted in 27,338 drug concentrations from 9,901 patients. Body size and composition, maturation and renal function were used to describe differences in drug clearance and volume of distribution. Results: This study demonstrates that GFR is a predictor of two distinct components of renal elimination clearance: (1) GFR clearance associated with normal GFR and (2) non-GFR clearance not associated with normal GFR. All three drugs had GFR clearance estimated as a drug-specific percentage of normal GFR (gentamicin 39%, amikacin 90% and vancomycin 57%). The total clearance (sum of GFR and non-GFR clearance), standardized to 70 kg total body mass, 176 cm, male, renal function 1, was 5.58 L/h (95% confidence interval [CI] 5.50-5.69) (gentamicin), 7.77 L/h (95% CI 7.26-8.19) (amikacin) and 4.70 L/h (95% CI 4.61-4.80) (vancomycin). Conclusions: GFR provides a physiological basis for renal drug elimination. It has been used to distinguish two elimination components. This physiological approach has been applied to describe clearance and volume of distribution from premature neonates to elderly adults with a wide dispersion of size, body composition and renal function. Dose individualization has been implemented using target concentration intervention.

Published
2024

11. A physiological approach to renal clearance: From premature neonates to adults.

Author

Holford, Nick, O'Hanlon, Conor J., Allegaert, Karel, Anderson, Brian, Falcão, Amilcar, Simon, Nicolas, Lo, Yoke‐Lin, Thomson, Alison H., Sherwin, Catherine M., Jacqz‐Aigrain, Evelyne, Llanos‐Paez, Carolina, Hennig, Stefanie, Mockus, Linas, and Kirkpatrick, Carl

Subjects
PREMATURE infants, NEWBORN infants, ADULTS, KIDNEY physiology, GLOMERULAR filtration rate, BODY composition
Abstract

Aims: We propose using glomerular filtration rate (GFR) as the physiological basis for distinguishing components of renal clearance. Methods: Gentamicin, amikacin and vancomycin are thought to be predominantly excreted by the kidneys. A mixed‐effects joint model of the pharmacokinetics of these drugs was developed, with a wide dispersion of weight, age and serum creatinine. A dataset created from 18 sources resulted in 27,338 drug concentrations from 9,901 patients. Body size and composition, maturation and renal function were used to describe differences in drug clearance and volume of distribution. Results: This study demonstrates that GFR is a predictor of two distinct components of renal elimination clearance: (1) GFR clearance associated with normal GFR and (2) non‐GFR clearance not associated with normal GFR. All three drugs had GFR clearance estimated as a drug‐specific percentage of normal GFR (gentamicin 39%, amikacin 90% and vancomycin 57%). The total clearance (sum of GFR and non‐GFR clearance), standardized to 70 kg total body mass, 176 cm, male, renal function 1, was 5.58 L/h (95% confidence interval [CI] 5.50‐5.69) (gentamicin), 7.77 L/h (95% CI 7.26‐8.19) (amikacin) and 4.70 L/h (95% CI 4.61‐4.80) (vancomycin). Conclusions: GFR provides a physiological basis for renal drug elimination. It has been used to distinguish two elimination components. This physiological approach has been applied to describe clearance and volume of distribution from premature neonates to elderly adults with a wide dispersion of size, body composition and renal function. Dose individualization has been implemented using target concentration intervention. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Key factors associated with 6‐thioguanine and 6‐methylmercaptopurine nucleotide concentrations in children treated by thiopurine for acute leukaemia and inflammatory bowel disease.

Author

de Beaumais, Tiphaine Adam, Lorrain, Simon, Mamhoudi, Naura, Simonin, Mathieu, Martinez Vinson, Christine, Medard, Yves, Petit, Arnaud, and Jacqz‐Aigrain, Evelyne

Subjects
INFLAMMATORY bowel diseases, AZATHIOPRINE, ACUTE leukemia, DRUG monitoring, LYMPHOBLASTIC leukemia, ERYTHROCYTES
Abstract

Aims: Azathioprine (AZA) and 6‐mercaptopurine are prescribed in acute lymphoblastic leukaemia (ALL) and inflammatory bowel diseases (IBD). Metabolism to active 6‐thioguanine (6TGN) and 6‐methylmercaptopurine nucleotides (6MMPN) is variable but therapeutic drug monitoring (TDM) remains debatable. This study reports on factors impacting on red blood cell (RBC) metabolites concentrations in children to facilitate TDM interpretation. Methods: The first paediatric TDM samples received during year 2021 were analysed, whatever indication and thiopurine drug. Target concentration ranges were 200–500, <6000 pmol/8 × 108 RBC for 6TGN and 6MMPN. Results: Children (n = 492) had IBD (64.8%), ALL (22.6%) or another autoimmune disease (12.6%): mean ages at TDM were 7.5 in ALL and 13.7 years in IBD (P <.0001). ALL received 6‐mercaptopurine (mean dose 1.7 mg/kg/d with methotrexate), IBD received AZA (1.9 mg/kg/d with anti‐inflammatory drugs and/or monoclonal antibodies). Median 6TGN and 6MMPN concentrations were 213.7 [interquartile range: 142.5; 309.6] and 1144.6 [419.4; 3574.3] pmol/8 × 108 RBC, 38.8% of patients were in the recommended therapeutic range for both compounds. Aminotransferases and blood tests were abnormal in 57/260 patients: 8.1% patients had high alanine aminotransaminase, 3.4% of patients had abnormal blood count. Factors associated with increased 6TGN were age at TDM and thiopurine methyltransferase genotype in ALL and AZA dose in IBD. The impact of associated treatment in IBD patients was also significant. Conclusion: TDM allowed identification of children who do not reach target levels or remain over treated. Including TDM in follow‐up may help physicians to adjust dosage with the aim of reducing adverse effects and improve treatment outcome. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Favorable pharmacokinetics and pharmacodynamics properties of Gilteritinib in cerebrospinal fluid: a potential effective treatment in relapsing meningeal acute myeloid leukaemia FLT3-ITD patients

Author

Vignal, Nicolas, primary, Kelly, Loïs, additional, Lengline, Etienne, additional, Cabannes-Hamy, Aurélie, additional, Siavellis, Justine, additional, Ghez, David, additional, Sauvageon, Hélène, additional, Braun, Thorsten, additional, Jacqz-Aigrain, Evelyne, additional, Kohn, Milena, additional, Rousselot, Philippe, additional, Puissant, Alexandre, additional, Raffoux, Emmanuel, additional, Mourah, Samia, additional, and Goldwirt, Lauriane, additional

Published
2023
Full Text
View/download PDF

18. How paediatric drug development and use could benefit from OMICs:A c4c expert group white paper

Author

Neumann, Eva, Schreeck, Filippa, Herberg, Jethro, Jacqz Aigrain, Evelyne, Maitland-van der Zee, Anke H., Pérez-Martínez, Antonio, Hawcutt, Daniel B., Schaeffeler, Elke, Rane, Anders, de Wildt, Saskia N., Schwab, Matthias, Neumann, Eva, Schreeck, Filippa, Herberg, Jethro, Jacqz Aigrain, Evelyne, Maitland-van der Zee, Anke H., Pérez-Martínez, Antonio, Hawcutt, Daniel B., Schaeffeler, Elke, Rane, Anders, de Wildt, Saskia N., and Schwab, Matthias

Abstract

The safety and efficacy of pharmacotherapy in children, particularly preterms, neonates and infants, is limited by a paucity of good-quality data from prospective clinical drug trials. A specific challenge is the establishment of valid biomarkers. OMICs technologies may support these efforts by complementary information about targeted and nontargeted molecules through systematic characterization and quantitation of biological samples. OMICs technologies comprise at least genomics, epigenomics, transcriptomics, proteomics, metabolomics and microbiomics in addition to the patient's phenotype. OMICs technologies are in part hypothesis-generating, allowing an in depth understanding of disease pathophysiology and pharmacological mechanisms. Application of OMICs technologies in paediatrics faces major challenges before routine adoption. First, developmental processes need to be considered, including a subdivision into specific age groups as developmental changes clearly impact OMICs data. Second, compared to the adult population, the number of patients is limited as are the type and amount of necessary biomaterial, especially in neonates and preterms. Thus, advanced trial designs and biostatistical methods, noninvasive biomarkers, innovative biobanking concepts including data and samples from healthy children, as well as analytical approaches (eg liquid biopsies) should be addressed to overcome these obstacles. The ultimate goal is to link OMICs technologies with innovative analysis tools, such as artificial intelligence at an early stage. The use of OMICs data based on a feasible approach will contribute to the identification complex phenotypes and subpopulations of patients to improve the development of medicines for children with potential economic advantages.

Published
2022

19. A loss-of-function IFNAR1 allele in Polynesia underlies severe viral diseases in homozygotes

Author

Bastard, Paul, primary, Hsiao, Kuang-Chih, additional, Zhang, Qian, additional, Choin, Jeremy, additional, Best, Emma, additional, Chen, Jie, additional, Gervais, Adrian, additional, Bizien, Lucy, additional, Materna, Marie, additional, Harmant, Christine, additional, Roux, Maguelonne, additional, Hawley, Nicola L., additional, Weeks, Daniel E., additional, McGarvey, Stephen T., additional, Sandoval, Karla, additional, Barberena-Jonas, Carmina, additional, Quinto-Cortés, Consuelo D., additional, Hagelberg, Erika, additional, Mentzer, Alexander J., additional, Robson, Kathryn, additional, Coulibaly, Boubacar, additional, Seeleuthner, Yoann, additional, Bigio, Benedetta, additional, Li, Zhi, additional, Uzé, Gilles, additional, Pellegrini, Sandra, additional, Lorenzo, Lazaro, additional, Sbihi, Zineb, additional, Latour, Sylvain, additional, Besnard, Marianne, additional, Adam de Beaumais, Tiphaine, additional, Jacqz Aigrain, Evelyne, additional, Béziat, Vivien, additional, Deka, Ranjan, additional, Esera Tulifau, Litara, additional, Viali, Satupa‘itea, additional, Reupena, Muagututi‘a Sefuiva, additional, Naseri, Take, additional, McNaughton, Peter, additional, Sarkozy, Vanessa, additional, Peake, Jane, additional, Blincoe, Annaliesse, additional, Primhak, Sarah, additional, Stables, Simon, additional, Gibson, Kate, additional, Woon, See-Tarn, additional, Drake, Kylie Marie, additional, Hill, Adrian V.S., additional, Chan, Cheng-Yee, additional, King, Richard, additional, Ameratunga, Rohan, additional, Teiti, Iotefa, additional, Aubry, Maite, additional, Cao-Lormeau, Van-Mai, additional, Tangye, Stuart G., additional, Zhang, Shen-Ying, additional, Jouanguy, Emmanuelle, additional, Gray, Paul, additional, Abel, Laurent, additional, Moreno-Estrada, Andrés, additional, Minster, Ryan L., additional, Quintana-Murci, Lluis, additional, Wood, Andrew C., additional, and Casanova, Jean-Laurent, additional

Published
2022
Full Text
View/download PDF

20. How paediatric drug development and use could benefit from OMICs: A c4c expert group white paper

Author

Neumann, Eva, primary, Schreeck, Filippa, additional, Herberg, Jethro, additional, Jacqz Aigrain, Evelyne, additional, Maitland‐van der Zee, Anke H., additional, Pérez‐Martínez, Antonio, additional, Hawcutt, Daniel B., additional, Schaeffeler, Elke, additional, Rane, Anders, additional, de Wildt, Saskia N., additional, and Schwab, Matthias, additional

Published
2022
Full Text
View/download PDF

21. Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial

Author

Hill, Louise F, primary, Clements, Michelle N, additional, Turner, Mark A, additional, Donà, Daniele, additional, Lutsar, Irja, additional, Jacqz-Aigrain, Evelyne, additional, Heath, Paul T, additional, Roilides, Emmanuel, additional, Rawcliffe, Louise, additional, Alonso-Diaz, Clara, additional, Baraldi, Eugenio, additional, Dotta, Andrea, additional, Ilmoja, Mari-Liis, additional, Mahaveer, Ajit, additional, Metsvaht, Tuuli, additional, Mitsiakos, George, additional, Papaevangelou, Vassiliki, additional, Sarafidis, Kosmas, additional, Walker, A Sarah, additional, Sharland, Michael, additional, Hill, Louise F, additional, Clements, Michelle, additional, Bafadal, Basma, additional, Alarcon Allen, Ana, additional, Anatolitou, Fani, additional, Del Vecchio, Antonio, additional, Giuffrè, Mario, additional, Karachristou, Korina, additional, Manzoni, Paolo, additional, Martinelli, Stefano, additional, Moriarty, Paul, additional, Nika, Angeliki, additional, Papaevangelou, Vana, additional, Roehr, Charles, additional, Sanchez Alcobendas, Laura, additional, Siahanidou, Tania, additional, Tzialla, Chryssoula, additional, Bonadies, Luca, additional, Booth, Nicola, additional, Catalina Morales-Betancourt, Paola, additional, Cordeiro, Malaika, additional, de Alba Romero, Concha, additional, de la Cruz, Javier, additional, De Luca, Maia, additional, Farina, Daniele, additional, Franco, Caterina, additional, Gialamprinou, Dimitra, additional, Hallik, Maarja, additional, Ilardi, Laura, additional, Insinga, Vincenzo, additional, Iosifidis, Elias, additional, Kalamees, Riste, additional, Kontou, Angeliki, additional, Molnar, Zoltan, additional, Nikaina, Eirini, additional, Petropoulou, Chryssoula, additional, Reyné, Mar, additional, Tataropoulou, Kassandra, additional, Triantafyllidou, Pinelopi, additional, Vontzalidis, Adamantios, additional, and Sharland, Mike, additional

Published
2022
Full Text
View/download PDF

22. [Practical management during maintenance therapy of pediatric acute lymphoblastic leukemia: Recommendations of the French Society for Childhood and Adolescent Cancer and Leukemia (SFCE)].

Author

Saultier P, Simonin M, Beaumais TA, Rialland F, Alby-Laurent F, Lubnau M, Desplantes C, Jacqz-Aigrain E, Rohrlich P, Reguerre Y, Rabian F, Sirvent N, Plat GW, and Petit A

Subjects
Child, Adolescent, Humans, Antineoplastic Combined Chemotherapy Protocols, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy
Abstract

Maintenance therapy is the last phase of treatment for acute lymphoblastic leukemia in children and adolescents. Although maintenance therapy is associated with toxicities and specific management issues, it is an essential phase of treatment that reduces the risk of relapse. The objective of this work is to propose a guide for the initiation, administration, and monitoring of maintenance therapy, and for the management of food, schooling, leisure, community life, risk of infection and links with family medicine., (Copyright © 2022 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results